Diana is a 44-year-old woman with opioid use disorder who has been stable on buprenorphine for two years. She tells you she has been reading about ibogaine online and is thinking about stopping buprenorphine and traveling to a clinic in Mexico for ibogaine treatment instead. She’s heard it can “reset” the brain’s response to opioids and eliminate cravings after a single session. She wants to know what you think.

Interest in ibogaine has surged. Media coverage is broader, veteran advocacy is louder, and in April 2026 the White House issued an executive order directing the FDA and DEA to accelerate research and access to psychedelics, naming ibogaine specifically (www.tinyurl.com/3hav3d52). Your patients are noticing. Many will ask whether ibogaine can do what they have heard, such as end withdrawal, eliminate cravings, and fix opioid addiction in a single session. There is some signal behind some of these claims, but the evidence is thin and the safety problems are serious. Here is what you need to know to have that conversation.

What is ibogaine?
Ibogaine is a psychoactive alkaloid from the root bark of Tabernanthe iboga, a plant used in spiritual and ceremonial practices in western Central Africa (Glick SD and Maisonneuve IM, Ann N Y Acad Sci 1998;844(1):214–226). In the US, it is a Schedule I substance with no approved medical use. The April executive order directed federal agencies to clear the way for research and possible access under the Right to Try Act, but ibogaine remains illegal to administer outside an FDA-sanctioned trial (www.tinyurl.com/bdzdja3f). Patients who want it must travel, usually to Mexico; however, ibogaine is also available in Brazil, Costa Rica, the Netherlands, and New Zealand, with its legal status and oversight varying widely between countries (Mash DC, Pharmacol Res 2023;190:106620).

Ibogaine’s pharmacology is complex. It antagonizes NMDA receptors and interacts with mu and kappa opioid receptors, among others (Litjens RPW and Brunt TM, Clin Toxicol (Phila) 2016;54(4):297–302). Its main metabolite, noribogaine, forms via CYP2D6 metabolism and has a much longer half-life, which may explain why some patients describe sustained effects. The combined action on glutamate, opioid, and serotonergic systems underlies the theory that ibogaine reduces withdrawal while also resetting reward circuits.

What does the evidence show?
Overall, the evidence base for ibogaine is very limited. There are no large RCTs. Most data come from case series, observational studies, retrospective cohorts, and small open-label trials (Köck P et al, J Subst Abuse Treat 2022;138:108717). The studies are small, uncontrolled, use different doses, and have short follow-up.

Within those limits, ibogaine does appear to reduce acute opioid withdrawal and cravings within 24–48 hours (Malcolm BJ et al, J Psychoactive Drugs 2018;50(3):256–265). Some patients also report improvement in depressive symptoms (Mosca A et al, Curr Neuropharmacol 2023;21(11):2178–2194). Whether these effects last is unknown. No published study has adequate long-term follow-up, so the claim that ibogaine “resets” the brain or produces lasting remission after one session is not supported.

Patients also frequently describe a mystical or spiritual experience during treatment, which fits with what is seen with other classical psychedelics (Brown TK et al, J Psychoactive Drugs 2019;51(2):155–165). The harder question—whether the experience itself leads to a meaningful clinical effect—remains open.

Safety: Cardiac concerns and more
Cardiac concerns
The main safety concern is cardiac. Ibogaine blocks hERG potassium channels, delaying cardiac repolarization, prolonging the QT interval, and increasing the risk of ventricular arrhythmias, including torsades de pointes. These are not theoretical risks:

• A 2016 toxicology review identified at least 27 fatalities following ibogaine ingestion; additional deaths and life-threatening events continue to accumulate (Litjens and Brunt, 2016).
• A subsequent systematic review identified cardiac toxicity, particularly QT prolongation, as the most common adverse effect, along with other persistent cardiac, psychiatric, and neurological effects (Ona G et al, Psychopharmacology (Berl) 2022;239(6):1977–1987).
• Ibogaine’s degree of QT prolongation is very large. One observational trial found that the average QT prolongation was 95 msec, with 50% of subjects developing a QTc greater than 500 msec (Knuijver T et al, Addiction 2022;117(1):118–128). For context, methadone prolongs QTc by an average of 10–15 msec.

Nor are cardiac events limited to high-risk patients:

• Case reports have documented fatal arrhythmias at therapeutic doses and in individuals without preexisting cardiac conditions (Brunt TM, Addiction 2026;121(6):1616–1621).
• A recent UK poison center case series reinforced these concerns, finding that six of seven reported ibogaine exposures involved cardiotoxicity, including cardiac arrest and torsades de pointes (Edwards EP et al, Clin Toxicol (Phila) 2025;63(3):212–216).

Other safety risks
Ibogaine can also cause ataxia, nausea, and intense psychological effects, including hallucinations and, in rare cases, mania or psychosis (Cherian K et al, Am J Ther 2024;31(2):e133–e140). These effects can be unpredictable, particularly in clinics without good screening or monitoring.

Metabolism varies. Drug levels can vary substantially across individuals depending on CYP2D6 activity, and the relative contributions of ibogaine and noribogaine are not fully understood (Knuijver T et al, J Psychopharmacol 2024;38(5):481–488).

Because ibogaine is not legally available in the US, patients who pursue treatment go abroad, where the quality of care varies widely. Some clinics may offer cardiac screening and monitoring, while others provide minimal oversight. There is no consensus on what constitutes adequate evaluation, nor is there a standardized approach to dosing, monitoring, or follow-up; in addition, you will usually not be involved in a patient’s care.

Talking with patients about ibogaine
Acknowledge what they have heard
When your patient asks about ibogaine, you might say: “I understand why this is getting attention. People are saying ibogaine can quickly reduce withdrawal and cravings, and there is some evidence behind that.” Then give them the rest of the picture: “But the research is very limited. The studies are small, and we don’t know how people do over the long term.”

Be direct about the risks
Explain: “My main concern is your heart. Ibogaine can cause fatal arrhythmias, even in people with healthy hearts.” Then explain the practical problem: “There are no agreed-upon dosing standards, who should be screened out, or how the heart should be monitored afterward. The quality of clinics varies a lot, and I won’t be involved in your care while you’re there.”

Anchor your patient in evidence-based treatments
Reinforce the established science: “We already have medications that are effective and that we understand well: buprenorphine and methadone. They reduce withdrawal and cravings, keep people in treatment, improve quality of life, and cut overdose deaths. Plus, we know how to prescribe them safely and how people do on them for a long time.”

Consider “elicit-educate-elicit” dialogue
This is a technique grounded in motivational interviewing that can foster deeper discussion:

• Elicit two-way communication: “I am glad you shared your interest with me. Would it be okay if I shared what we know now about ibogaine?”
• Provide education: “Research shows...”
• Elicit feedback: “So, what does this mean for you?”

Since Diana is already stable on buprenorphine, the message is straightforward: The treatment that has kept her well for two years is the better choice. You validate her curiosity and note that her interest in ibogaine is reasonable, but clearly state that swapping a treatment with strong evidence and a known safety profile for one with thin evidence and serious cardiac risk is not a trade worth making.

CARLAT VERDICT
Ibogaine may help with opioid withdrawal and cravings, but the cardiac risks are serious, and the evidence is too sparse to recommend it. When patients ask, redirect them to buprenorphine or methadone—treatments that are well studied, safe, and effective.